Strategies for the Prevention or Treatment of Acute Kidney Injury in COVID-19 Infection

Event Details

Objectives

The purpose of this meeting was to create a forum to bring together investigators in the field interested in discussing drug development pathways and how to plan and execute meaningful clinical trials.

Video Recording
PowerPoint Presentation (PDF, 402.23 KB)
Meeting Summary (PDF, 175.38 KB)

Agenda

Zoom meeting on March 26, 2020

11:00 a.m. – 11:05 a.m.

Introduction
Dr. Robert Star, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

11:05 a.m. – 11:45 a.m.

Discussion
Drs. Paul Kimmel and Ivonne Schulman, NIDDK
What is your current experience with COVID-19–associated AKI incidence and outcomes in hospital, especially intensive care units?
What is needed now and for the fall?
Are agents and drugs “shovel-ready” for phase 2 testing?

11:45 a.m. – 11:55 a.m.

Questions to NIDDK Program Officers
NIH Resources—NCATS’ screening platforms, Notice of Special Interest

11:55 a.m. – 12:00 p.m.

Concluding Comments
Dr. Robert Star, NIDDK
Interest in future meetings
Volunteer leaders